RxDoctor Payments Data

Elizabeth Swisher

Gynecologic Oncology · Seattle, WANPI 1902986979

Payments from drug & device makers

What this record shows

This record is dominated by education: $156 of the $156 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Clovis Oncology, Inc.. That places this record below the midpoint for gynecologic oncology clinicians in WA, where the typical reported total is $778.

$156in general payments, 2019–2025

Across 4 payments — averaging $38.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Clovis Oncology, Inc.$156
$7,960,970in research payments, 2019–2025

Across 190 payments — averaging $41,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$7.1M
  • AbbVie$391K
  • Clovis Oncology, Inc.$278K
  • Tesaro, Inc.$156K
  • AstraZeneca$10K

What the payments were for

  • Education$156100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Clovis Oncology, Inc.4$156

How this compares

$156 in reported general payments places this provider in the 20th percentile of 36 gynecologic oncology providers in Washington.

See all gynecologic oncology providers in Washington

Medicare billing

Part B allowed, 2024
$15,152
Medicare patients
33
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →